Avraham Ben-Tzvi - 01 Oct 2025 Form 4 Insider Report for TITAN PHARMACEUTICALS INC (TTNP)

Role
Director
Signature
/s/ Avraham Ben-Tzvi
Issuer symbol
TTNP
Transactions as of
01 Oct 2025
Net transactions value
$0
Form type
4
Filing time
08 Oct 2025, 20:21:28 UTC
Previous filing
28 Feb 2025
Next filing
23 Dec 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Ben-Tzvi Avraham Director 44 ZAYT SHEMEN ST., FLAT 4, EFRAT, ISRAEL /s/ Avraham Ben-Tzvi 08 Oct 2025 0001944721

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TTNP Common Stock Disposed to Issuer -3,313 -100% 0 01 Oct 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TTNP Option to Purchase Common Stock Disposed to Issuer -1,250 -100% 0 01 Oct 2025 Common Stock 1,250 Direct F2
transaction TTNP Option to Purchase Common Stock Disposed to Issuer -5,000 -100% 0 01 Oct 2025 Common Stock 5,000 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Disposed of pursuant to the Merger and Contribution and Share Exchange Agreement, dated as of August 19, 2024 (the "Merger Agreement"), by and among Titan Pharmaceuticals, Inc. ("Titan"), Black Titan Corporation ("Black Titan"), TTNP Merger Sub, Inc., a direct wholly owned subsidiary of Black Titan ("Merger Sub") and TalenTec Sdn. Bhd, in exchange for 1 ordinary share of Black Titan common stock for each share of Titan common stock on the effective date of the merger (the "Merger").
F2 Options issued pursuant to Titan's 2015 Omnibus Equity Incentive Plan with an exercise price equal to the closing price of Titan's common stock on August 15, 2022. These options were assumed by Black Titan in the Merger and exchanged for 1 Black Titan option for each Titan option.
F3 Options issued pursuant to Titan's 2015 Omnibus Equity Incentive Plan with an exercise price equal to the closing price of Titan's common stock on September 15, 2022. These options were assumed by Black Titan in the Merger and exchanged for 1 Black Titan option for each Titan option.